OncRef

Clinical Trial: NCT03742102

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-08-04

Study Overview

Brief Summary

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Official Title

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Conditions

Triple Negative Breast Neoplasms

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Capivasertib
  • Drug: Oleclumab
  • Drug: Paclitaxel
  • Drug: Trastuzumab deruxtecan
  • Drug: Datopotamab deruxtecan

Other Study ID Numbers

  • D933LC00001
  • 2018-000764-29
  • 2018

Start Date (Actual)

2018-12-21

Primary Completion Date (Actual)

2024-11-29

Study Completion Date (Estimated)

2027-02-26

Enrollment (Actual)

243

Study Type

Interventional

Phase

Phase 1, Phase 2